Latest Commercialization News

BrainChip Holdings has initiated tape-out for its AKD1500 neuromorphic AI chip, targeting volume production by late Q3 2026 to meet rising demand for ultra-low-power edge AI solutions.

BCAL Diagnostics has established a $10 million convertible note facility, with $5 million already committed, to accelerate its cancer detection technologies and commercial milestones.

Dreadnought Resources has commenced drilling at the Stinger rare earth and niobium target within its Mangaroon project, revealing a substantial rare earth enriched carbonatite zone with promising grades and mineralogy akin to the Mountain Pass deposit.

Black Cat Syndicate reports visible antimony mineralisation in initial drill holes at Mt Clement, advancing one of Australia’s largest antimony deposits with assays due in November 2025.

Podium Minerals has achieved a metallurgical breakthrough at its Parks Reef project, delivering an 80% recovery of key metals and a 50-fold concentrate grade upgrade. The company is advancing a A$12 million capital raise to accelerate development amid soaring platinum and palladium prices.

Euro Manganese is pushing forward an optimization program for its Chvaletice Manganese Project to enhance operational efficiency and reduce costs, aligning with surging global demand for high-purity manganese critical to electric vehicle batteries and energy storage.

Botanix Pharmaceuticals reports a strong start to FY26 with a 50% surge in Sofdra prescriptions and a 65% rise in net revenue, underpinned by a larger sales team and operational efficiencies.

Veris Limited has acquired Melbourne-based Mesh Livable Communities and a 50% stake in the Parsel digital platform, boosting its urban planning and digital consulting capabilities. The deal, valued at up to AUD 3.18 million plus AUD 0.5 million for equity, is expected to be earnings accretive and strengthen Veris’ presence across Australia’s property and planning sectors.

Viridis Mining and Minerals has secured a prime site and finalized key contracts for its Rare Earth Research and Processing Centre in Brazil, positioning itself as a critical Western-aligned rare earth supplier amid tightening Chinese export controls.

Vectus Biosystems has agreed to sell its VB4-P5 renal fibrosis compound to Canadian biotech XORTX Therapeutics for US$3 million in shares and warrants, gaining a strategic equity position while refocusing on its cardiovascular and fibrosis pipeline.

Zoono Group Limited has responded to an ASX price query following a recent surge in its share price and trading volume, confirming no undisclosed information exists and attributing market activity to ongoing shelf-life extension trials across multiple continents.

Multistack International Limited has announced plans to discontinue its current business operations due to sustained losses and capital constraints, with a strategic disposal of its Australian subsidiary underway.